Abstract: An aluminum fin material includes an aluminum plate, an erosion-resistant coating layer on a surface of the aluminum plate, and a hydrophilic coating layer formed on a surface of the erosion-resistant coating layer. The erosion-resistant coating layer contains an acrylic resin and fluororesin particles, an amount of the erosion-resistant coating layer is 0.05 mg/dm2 or more and 8.00 mg/dm2 or less, and a content of the fluororesin particles in the erosion-resistant coating layer is 0.05 mass % or more and 8.00 mass % or less.

Abstract: A thermoplastic resin composition comprising; a thermoplastic resin (A) selected from the group consisting of an aromatic polycarbonate resin (A1), a styrene-based resin (A2), an aromatic polyester resin (A3), a polyphenylene ether resin (A4), a methacrylic resin (A5), a polyarylene sulfide resin (A6), an olefin resin (A7), a polyamide resin (A8), and mixtures thereof; a hydrophilic copolymer (B) having a polyoxyethylene chain; and a fatty acid metal salt (C) represented by the following formula (1): M(OH)y(R—COO)x . . . (1), wherein R is an alkyl group or alkenyl group having 6 to 40 carbon atoms; M is at least one metal element selected from the group consisting of aluminum, zinc, calcium, magnesium, lithium, and barium; and x and y each independently represent an integer of 0 or more, and satisfy the relation represented by x+y=[valency of M].

Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen atom; m represents an integer of from 1 to 3; and n represents zero or 1, or relates to a pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen atom; m represents an integer of from 1 to 3; and n represents zero or 1, or relates to a pharmaceutically acceptable salts thereof.

Abstract: [Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.